Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
about
LC-MS/MS analysis of metformin, saxagliptin and 5-hydroxy saxagliptin in human plasma and its pharmacokinetic study with a fixed-dose formulation in healthy Indian subjects.Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines.Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.
P2860
Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Clinical Pharmacokinetics and ...... eptidyl Peptidase-4 Inhibitor.
@en
type
label
Clinical Pharmacokinetics and ...... eptidyl Peptidase-4 Inhibitor.
@en
prefLabel
Clinical Pharmacokinetics and ...... eptidyl Peptidase-4 Inhibitor.
@en
P2860
P1476
Clinical Pharmacokinetics and ...... eptidyl Peptidase-4 Inhibitor.
@en
P2093
David W Boulton
P2860
P2888
P356
10.1007/S40262-016-0421-4
P577
2016-06-09T00:00:00Z
P6179
1044840837